Susquehanna International Group, LLP Regulus Therapeutics Inc. Call Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$1.79 - $2.8 $158,415 - $247,799	-88,500 Reduced 43.75%	113,800 $203,000
Q1 2024 May 07, 2024	BUY	$1.13 - $2.88 $187,127 - $476,928	165,600 Added 451.23%	202,300 $582,000
Q4 2023 Feb 14, 2024	BUY	$1.21 - $1.44 $1,815 - $2,160	1,500 Added 4.26%	36,700 $46,000
Q3 2023 Nov 14, 2023	SELL	$1.27 - $1.76 $11,176 - $15,488	-8,800 Reduced 20.0%	35,200 $48,000
Q2 2023 Aug 11, 2023	BUY	$0.87 - $1.75 $2,871 - $5,775	3,300 Added 8.11%	44,000 $64,000
Q1 2023 May 16, 2023	SELL	$0.79 - $1.61 $1,343 - $2,737	-1,700 Reduced 4.01%	40,700 $34,000
Q4 2022 Feb 14, 2023	BUY	$1.17 - $1.85 $4,563 - $7,215	3,900 Added 10.13%	42,400 $58,000
Q3 2022 Nov 14, 2022	BUY	$1.35 - $2.39 $20,655 - $36,567	15,300 Added 65.95%	38,500 $65,000
Q2 2022 Aug 15, 2022	BUY	$1.6 - $3.4 $37,120 - $78,880	23,200 New	23,200 $48,000

53M

155K

34.2K

Ticker RGLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,634,400
Market Cap $21.8M
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.